On 15 October, Lonza will host a free 60-minute webinar that will address current concerns regarding the use of serum in cell culture media, explore viable alternatives and provide guidance on how to adapt cells to a serum-free environment.
Basel, Switzerland, 1 October 2019 – On 15 October, Lonza will host a free 60-minute webinar that will address current concerns regarding the use of serum in cell culture media, explore viable alternatives and provide guidance on how to adapt cells to a serum-free environment.
In cell biology, cells are commonly grown in medium supplemented with serum. Serum is a highly variable, undefined product, which impacts the reliability, reproducibility and consistency of scientific results. In order to eliminate these unwanted influences, more and more scientists are considering serum-free cell culturing.
In the webinar titled “Cell culture media: Why go serum-free?”, Nicole Wellens, Lonza Cell Culture Specialist, will discuss the following topics:
· Scientific concerns about cell culturing with serum
· The case for serum-free cell culture
· How to switch from serum to serum-free culturing with little effort
More information about attending the webinar is available here.
Cell culture media: Why go serum-free?
Speaker: Nicole Wellens; Moderator: Heiko Büth
Tuesday, 15 October 2019
· 8 AM PDT (Los Angeles)
· 11 AM EDT (New York)
· 4 PM BST (London)
· 5 PM CEST (Berlin)
Further information can be found on the serum-free cell culture web page. By registering interest in the webinar, participants will also receive a link once it is available to view the webinar “on demand” via the Lonza website.
More information about Lonza’s upcoming and on-demand webinars is available here: www.lonza.com/webinars
About Lonza
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Lonza Contact Details
Lonza Cologne GmbH
Manager Marketing Communications
Petra Haberkamm
Tel +49 221 991990
petra.haberkamm@lonza.com
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
